Revvity, Inc. (NYSE: RVTY) shares closed at $108.80, up 0.29% on the day, after the company reported its fourth-quarter financial results and provided an update on full-year performance and guidance.
Market Capitalization
At the close of trading, the company’s market capitalization stood at approximately USD 12.34 billion.
Latest Quarterly Results (Q4 FY25)
For the fourth quarter ended December 2025, Revvity reported consolidated revenue of $772.1 million, compared with $729.4 million in the same quarter last year, representing year-over-year growth of about 6% on a reported basis and 4% on an organic basis. GAAP net income for the quarter was $98.4 million, compared with $94.6 million a year earlier. Diluted earnings per share were $0.87. On an adjusted basis, earnings per share from continuing operations were reported at $1.70. Adjusted operating income from continuing operations totaled $229.4 million, resulting in an adjusted operating margin of 29.7%. Life Sciences segment revenue for the quarter was $382.0 million, with adjusted operating income of $136.0 million. Diagnostics segment revenue was $390.1 million, with adjusted operating income of $91.4 million.
Financial Trends
Chart 1 — Operating Performance: Quarterly revenue trend
Chart 2 — Market Performance: One-month stock price trend
Full-Year Results Context
For the full fiscal year, Revvity reported revenue of $2.86 billion, compared with $2.83 billion in the prior year. GAAP net income for the year was $346.9 million, versus $349.3 million in the previous year. Full-year performance reflected mixed trends across operating segments, with Diagnostics contributing incremental organic growth, while Life Sciences results remained broadly stable year over year.
Business & Operations Update
During the quarter, the company continued to focus on execution across its Life Sciences and Diagnostics businesses. Management highlighted ongoing investments in diagnostics workflows and selective product introductions aligned with existing platforms. Operational activity during the period primarily reflected previously disclosed integration initiatives, internal efficiency measures, and continued portfolio discipline.
M&A or Strategic Moves
The company did not announce any new mergers, acquisitions, or divestitures during the quarter. No new strategic transactions were disclosed, and previously completed portfolio actions continue to be integrated as outlined in earlier regulatory filings.
Equity Analyst Commentary
Following the earnings release, institutional research commentary noted that reported revenue and adjusted earnings per share exceeded prevailing market expectations for the quarter. Analyst summaries cited Diagnostics performance as a contributor to quarterly results, while Life Sciences trends were described as stable. Commentary focused on reported financial outcomes.
Guidance & Outlook — what to watch for
The company issued full-year 2026 guidance, indicating expected revenue in the range of $2.96 billion to $2.99 billion and adjusted earnings per share between $5.35 and $5.45. Areas to watch include quarterly progress toward these ranges, organic growth trends across segments, and updates provided in subsequent filings.
Performance Summary
Revvity shares closed up 0.29% on the day. Fourth-quarter revenue totaled $772.1 million, with adjusted earnings per share of $1.70. Diagnostics continued to show higher organic growth relative to Life Sciences during the period.